Two monoclonal antibodies (Inmazeb and Ebanga) were approved for the treatment of Zaire ebolavirus (Ebolavirus) infection in adults and children by the US Food and Drug Administration in late 2020. Early supportive care with rehydration, symptomatic treatment improves survival.Vaccines to protect against Ebola have been developed and have been used to help control the spread of Ebola outbreaks in Guinea and in the Democratic Republic of the Congo (DRC).Good outbreak control relies on applying a package of interventions, namely case management, infection prevention and control practices, surveillance and contact tracing, a good laboratory service, safe and dignified burials and social mobilisation.Community engagement is key to successfully controlling outbreaks.Case fatality rates have varied from 25% to 90% in past outbreaks. The average EVD case fatality rate is around 50%.The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a rare but severe, often fatal illness in humans.
|
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |